Skip to main content
. 2011 Jun 6;2011:1502.
Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Health-related quality of life
[65]
Systematic review
712 people with COPD
2 RCTs in this analysis
Mean change from baseline in Chronic Respiratory Disease Questionnaire 6 months
10 with fluticasone plus salmeterol
5 with placebo

WMD 5.0
95% CI 2.48 to 7.52
P = 0.0001
Effect size not calculated fluticasone plus salmeterol
[65]
Systematic review
3346 people with COPD
4 RCTs in this analysis
Mean change in St George's Respiratory Questionnaire (SGRQ) 6 months to 3 years
with fluticasone plus salmeterol
with placebo
Absolute numbers not reported

–2.9 units
95% CI –3.61 units to –2.18 units
P <0.00001
Effect size not calculated fluticasone plus salmeterol
[65]
Systematic review
923 people with COPD
2 RCTs in this analysis
Mean change in SGRQ 12 months
with budesonide plus formoterol
with placebo
Absolute numbers not reported

–6.06 units v placebo
95% CI –7.90 units to –4.22 units
P <0.00001
Effect size not calculated budesonide plus formoterol
[68]
RCT
3-armed trial
224 people with COPD Change in SGRQ 4 weeks
–2.4 with fluticasone 500 micrograms plus salmeterol 50 micrograms twice daily
+1.5 with placebo

P <0.05
Effect size not calculated fluticasone plus salmeterol